Primary Site >> Pancreatic Cancer
Gene >> KDR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. PMID: 10585578 Ref: De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. PMID: 11054395 |
Ref: Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. PMID: 11274374 Ref: Expression of VEGF-C and activation of its receptors VEGFR-2 and VEGFR-3 in trophoblast. PMID: 11332691 |
Ref: Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice. PMID: 12464871 |
Ref: CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. PMID: 14522925 |
Ref: Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. PMID: 15476280 |
Ref: Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. PMID: 15701856 Ref: Molecularly targeted therapy for gastrointestinal cancer. PMID: 15892618 Ref: Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice. PMID: 16026649 Ref: Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. PMID: 16288027 |
Ref: Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. PMID: 16532435 Ref: Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer? PMID: 16621676 Ref: Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer. PMID: 16638876 Ref: Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. PMID: 16678129 Ref: Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts. PMID: 16791450 |
Ref: Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines. PMID: 17895890 |
Ref: SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. PMID: 18514780 Ref: Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. PMID: 18519694 Ref: Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. PMID: 19001434 Ref: Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. PMID: 19010843 Ref: The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. PMID: 19038046 Ref: Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells. PMID: 19043530 Ref: [A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer]. PMID: 19106593 Ref: Small molecule tyrosine kinase inhibitors in pancreatic cancer. PMID: 19707451 |
Ref: The Ape-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis. PMID: 19097035 Ref: [Treatments of epithelial ovarian cancer by histologic subtype]. PMID: 19223734 Ref: Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models. PMID: 19528458 Ref: Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. PMID: 19567820 Ref: An overview of small-molecule inhibitors of VEGFR signaling. PMID: 19736552 |
Ref: Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. PMID: 19930156 Ref: Significance of phospho-vascular endothelial growth factor receptor-2 expression in pancreatic cancer. PMID: 20367641 Ref: Bioluminescence imaging of angiogenesis in a murine orthotopic pancreatic cancer model. PMID: 20376570 Ref: Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a. PMID: 20488920 Ref: Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells. PMID: 20714148 Ref: Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer. PMID: 20927318 Ref: Nuclear receptor COUP-TFII controls pancreatic islet tumor angiogenesis by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor-2 signaling. PMID: 20978203 Ref: SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model. PMID: 22069683 |
Ref: Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging. PMID: 21339349 Ref: Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. PMID: 21390185 Ref: Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. PMID: 21622725 Ref: Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. PMID: 21885862 Ref: Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-alpha/VEGF/Rho-GTPases: pivotal role of STAT-3. PMID: 22016776 Ref: [The development of a novel cancer vaccine using Peptide vaccine for patients with advanced pancreatic cancer]. PMID: 22202233 |
Ref: Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. PMID: 20803052 Ref: High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer. PMID: 21822553 Ref: VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells. PMID: 22207048 Ref: Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients. PMID: 22461457 Ref: Novel dual inhibitors of vascular endothelial growth factor and VEGFR2 receptor. PMID: 22703300 Ref: Antitumor activity of emodin against pancreatic cancer depends on its dual role: promotion of apoptosis and suppression of angiogenesis. PMID: 22876305 Ref: Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer. PMID: 22906006 Ref: Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. PMID: 22935731 |
Ref: Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. PMID: 23211371 Ref: VEGFR-2, CXCR-2 and PAR-1 germline polymorphisms as predictors of survival in pancreatic carcinoma. PMID: 23293110 Ref: Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. PMID: 23422754 Ref: An intensified systemic trafficking of bone marrow-derived stem/progenitor cells in patients with pancreatic cancer. PMID: 23672538 Ref: Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis. PMID: 23890141 Ref: A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer. PMID: 23993964 Ref: Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody. PMID: 24023743 Ref: DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PMID: 24040120 Ref: Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. PMID: 24498547 |
Ref: Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models. PMID: 24327018 Ref: A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Espanol Multidisciplinario en Cancer Digestivo (GEMCAD) study. PMID: 24416138 Ref: P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma. PMID: 24633336 Ref: Embelin suppresses growth of human pancreatic cancer xenografts, and pancreatic cancer cells isolated from KrasG12D mice by inhibiting Akt and Sonic hedgehog pathways. PMID: 24694877 Ref: XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. PMID: 24880079 Ref: Expression of platelet-derived growth factor receptor beta is maintained by Prox1 in lymphatic endothelial cells and is required for tumor lymphangiogenesis. PMID: 24981766 Ref: Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. PMID: 25088418 Ref: Serous neoplasms of the pancreas share many, but not all aspects of their microvascular and angiogenic profile with low-grade clear cell renal cell carcinomas. PMID: 25155377 Ref: Gene therapy in pancreatic cancer. PMID: 25309069 |
Ref: Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection. PMID: 25322341 Ref: Basaloid carcinoma of the pancreas--clinicopathological presentation and oncogenetic snapshot of a rare entity. PMID: 25432630 Ref: A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer. PMID: 25519702 Ref: Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling. PMID: 25909285 Ref: Identification of TAX2 peptide as a new unpredicted anti-cancer agent. PMID: 26046793 Ref: Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines. PMID: 26087898 Ref: Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. PMID: 26137397 Ref: An Attempt to Evaluate Selected Aspects of "Bone-Fat Axis" Function in Healthy Individuals and Patients With Pancreatic Cancer. PMID: 26266370 Ref: Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors. PMID: 26445848 Ref: c-Met as a Target for Personalized Therapy. PMID: 26628860 Ref: VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature. PMID: 26710495 |
Ref: Multiple Pharmacological Properties of a Novel Parthenin Analog P16 as Evident by its Cytostatic and Antiangiogenic Potential Against Pancreatic Adenocarcinoma PANC -1 Cells. PMID: 26299660 Ref: RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. PMID: 26350096 Ref: Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling. PMID: 26597578 Ref: The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. PMID: 26874741 Ref: DSGOST inhibits tumor growth by blocking VEGF/VEGFR2-activated angiogenesis. PMID: 26967562 Ref: SH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2. PMID: 27105528 Ref: The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer. PMID: 27374084 Ref: Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors. PMID: 27798861 |
Ref: Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. PMID: 27783849 Ref: Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. PMID: 27861852 Ref: Triple-amiRNA VEGFRs inhibition in pancreatic cancer improves the efficacy of chemotherapy through EMT regulation. PMID: 27889393 Ref: Determination of VEGFR-2 (KDR) 604A>G Polymorphism in Pancreatic Disorders. PMID: 28218664 Ref: Emerging protein kinase inhibitors for treating pancreatic cancer. PMID: 28253828 Ref: Emerging antibodies for the treatment of pancreatic cancer. PMID: 28253833 Ref: Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. PMID: 28259610 Ref: CPEB4 immunohistochemical expression is associated to prognosis in stage IV colorectal carcinoma. PMID: 28551384 Ref: A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo. PMID: 28779210 Ref: Identification of the S100 fused-type protein hornerin as a regulator of tumor vascularity. PMID: 28916756 |
Ref: Association of cytosolic sialidase Neu2 with plasma membrane enhances Fas-mediated apoptosis by impairing PI3K-Akt/mTOR-mediated pathway in pancreatic cancer cells. PMID: 29434218 Ref: A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. PMID: 29632710 Ref: Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. PMID: 29765563 Ref: Traditional Chinese medicine Astragalus polysaccharide enhanced antitumor effects of the angiogenesis inhibitor apatinib in pancreatic cancer cells on proliferation, invasiveness, and apoptosis. PMID: 29785118 Ref: VEGF receptor-2/neuropilin 1 trans-complex formation between endothelial and tumor cells is an independent predictor of pancreatic cancer survival. PMID: 30027561 Ref: Tanshinone IIA can inhibit MiaPaCa2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways. PMID: 30226540 |